SQLite Web: event_store.db

Update row 64885 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-17T00:43:39.064220+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:d447d37710ae0285","evidence_event_ids":["evt_3cd38eaeead7"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/why-abbott-laboratories-stock-tumbled-thursday","as_of":"2026-04-17T00:43:39.064220+00:00","canonical_url":"https://www.fool.com/investing/2026/04/16/why-abbott-laboratories-stock-tumbled-on-thursday/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/why-abbott-laboratories-stock-tumbled-thursday","article_chars":3760,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_2845e2611c6179a3","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/16/why-abbott-laboratories-stock-tumbled-on-thursday/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-17T15:41:00.384936+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsInvestors had more of an issue with guidance.","fetched_title":"Why Abbott Laboratories Stock Tumbled on Thursday | Nasdaq","final_url":"https://www.nasdaq.com/articles/why-abbott-laboratories-stock-tumbled-thursday","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/why-abbott-laboratories-stock-tumbled-thursday","source_event_id":"evt_3cd38eaeead7","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"2d7ceb061b6380d4","kind":"unusual_volume","published_at":"2026-04-16T23:42:55+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["Thursday","late last month","first quarter","2025","2026"],"entities":[{"asset_class":"equity","name":"Abbott Laboratories","relevance":"high","symbol":"ABT","type":"company"},{"asset_class":"equity","name":"Exact Sciences","relevance":"medium","symbol":"","type":"company"}],"event_type":"earnings","information_gaps":["The signal type requests unusual volume delta (volume ratio vs average), but the provided text contains no volume figures or volume ratio data.","No explicit statement confirms whether the volume change (if any) was confirmed by news beyond the earnings/guidance narrative; the article discusses price reaction and guidance, not trading volume metrics.","A specific catalyst hypothesis for unusual volume is not provided in the text; only the guidance cut and Exact Sciences-related share dilution are discussed as the reason for the stock decline."],"key_facts":["Abbott\u2019s stock was down by 6% at market close on Thursday following the earnings release.","The article states first-quarter results \u201cmore or less met analyst estimates.\u201d","Investors\u2019 negative reaction is attributed to Abbott\u2019s \u201cnotable cut to its full-year profitability guidance.\u201d","Abbott reduced its full-year 2026 adjusted EPS estimate to $5.38 to $5.58, down from a previous forecast of $5.55 to $5.80.","Abbott expects comparable sales to rise by 6.5% to 7.5% over the 2025 result.","The article links the guidance cut to anticipated share dilution from Abbott\u2019s acquisition of Exact Sciences, which closed late last month.","The article states Abbott\u2019s first-quarter sales were just under $11.2 billion, nearly 8% higher year over year.","The article states non-GAAP (adjusted) profitability matched the consensus analyst forecast."],"numeric_claims":[{"label":"Stock move (market close)","value":"down 6%"},{"label":"First-quarter sales","value":"just under $11.2 billion"},{"label":"YoY sales growth (Q1)","value":"nearly 8%"},{"label":"First-quarter GAAP net income","value":"slightly more than $2 million"},{"label":"First-quarter EPS (GAAP)","value":"$1.15 per share"},{"label":"Full-year 2026 adjusted EPS estimate (new)","value":"$5.38 to $5.58"},{"label":"Full-year 2026 adjusted EPS estimate (previous)","value":"$5.55 to $5.80"},{"label":"Comparable sales growth expectation","value":"6.5% to 7.5%"}],"primary_claim":"Abbott\u2019s stock dropped ~6% on Thursday mainly because it cut its full-year adjusted profitability guidance, despite first-quarter results broadly meeting analyst expectations.","relevance_score":0.62,"sentiment":"negative","source_quality":"high","summary":"Abbott Laboratories (ABT) fell about 6% after reporting results that met expectations, with investors reacting primarily to a cut in full-year adjusted profitability guidance. The article attributes the guidance reduction to factoring in anticipated share dilution related to the recently closed Exact Sciences acquisition.","topics":["earnings","guidance cut","adjusted EPS","share dilution","Exact Sciences acquisition","medical devices growth"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsInvestors had more of an issue with guidance.","tickers":[],"title":"Why Abbott Laboratories Stock Tumbled on Thursday","url":"https://www.fool.com/investing/2026/04/16/why-abbott-laboratories-stock-tumbled-on-thursday/"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel